Cargando…

The cytotoxicity of gefitinib on patient‑derived induced pluripotent stem cells reflects gefitinib‑induced liver injury in the clinical setting

Gefitinib is a key drug used in the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Gefitinib therapy is superior to conventional chemotherapy for the progression-free survival rate of patients with EGFR mutations. However, 10–26% of patients develop grade 3 or higher hepatotoxi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujisaka, Yasuhito, Nakagawa, Takatoshi, Tomoda, Kiichiro, Watanabe, Marina, Matsunaga, Ninso, Tamura, Yosuke, Ikeda, Soichiro, Imagawa, Akihisa, Asahi, Michio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623090/ https://www.ncbi.nlm.nih.gov/pubmed/37927418 http://dx.doi.org/10.3892/ol.2023.14108

Ejemplares similares

Large Cell Neuroendocrine Carcinoma of the Lung with Cancer-Associated Retinopathy
por: Nakamura, Takahiko, et al.
Publicado: (2015)

Non-thermal atmospheric-pressure plasma potentiates mesodermal differentiation of human induced pluripotent stem cells
por: Kobayashi, Mime, et al.
Publicado: (2022)

Alitretinoin Treatment for Gefitinib-Induced Paronychia
por: Lee, Soo Young, et al.
Publicado: (2019)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Corrigendum to “Non-thermal atmospheric-pressure plasma potentiates mesodermal differentiation of human induced pluripotent stem cells” [Heliyon 8(12) (December 2022) e12009]
por: Mime Kobayashi, et al.
Publicado: (2023)

Induced 2C Expression and Implantation-Competent Blastocyst-like Cysts from Primed Pluripotent Stem Cells
por: Kime, Cody, et al.
Publicado: (2019)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line
por: Yan, Dong, et al.
Publicado: (2015)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

Rhabdomyolysis Caused by Gefitinib Overdose
por: Obayashi, Shohei, et al.
Publicado: (2021)

Gefitinib: Dermatitis: case report
Publicado: (2022)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Scanning Electron Microscopy of Subclinical Gefitinib-Induced Hair Changes
por: de Almeida, Hiram Larangeira, et al.
Publicado: (2020)

Gefitinib-induced pyogenic granuloma in a patient with lung cancer
por: Sahoo, Satyajeet, et al.
Publicado: (2020)

Endoplasmic Reticulum Stress Contributes to Gefitinib-Induced Apoptosis in Glioma
por: Chang, Cheng-Yi, et al.
Publicado: (2021)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines
por: Dratkiewicz, Ewelina, et al.
Publicado: (2018)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Gefitinib-induced interstitial pneumonia: A case report and review of the literature
por: LUO, CHANGQIN, et al.
Publicado: (2014)

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
por: Beom, Seung-Hoon, et al.
Publicado: (2016)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Intravenously Injected Pluripotent Stem Cell–derived Cells Form Fetomaternal Vasculature and Prevent Miscarriage in Mouse
por: Daimon, Atsushi, et al.
Publicado: (2020)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer
por: Zou, Zheng-Zhi, et al.
Publicado: (2015)

Treatment with gefitinib after erlotinib-induced liver injury: a case report
por: Nakatomi, Katsumi, et al.
Publicado: (2011)

FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer
por: Li, Jian, et al.
Publicado: (2022)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
por: Stoppoloni, Daniela, et al.
Publicado: (2010)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

Alkalescent soda beverage caused the disappearance of gefitinib-induced rashes and decreased efficacy in a non-small-cell lung cancer patient treated with gefitinib: A case report
por: Bian, Shuang, et al.
Publicado: (2020)

Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases
por: Yano, Yukihiro, et al.
Publicado: (2012)

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells
por: Zhu, Yinsong, et al.
Publicado: (2015)

M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR
por: Xiao, Fengqi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hceshfj3c88tevq9slerrudb0v